|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 409 12th Street, SW |
Address2 |
|
| City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
3. Principal place of business (if different than line 2)
| City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
|
5. Senate ID# 400578740-12
|
||||||||
|
6. House ID# 412490000
|
||||||||
| TYPE OF REPORT | 8. Year | 2025 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Kira Peterson |
Date | 4/18/2025 3:38:43 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Abortion access (general); Access to mifepristone (general); Contraception (general); Maternal mortality and morbidity (general); Advancing Safe Medications for Moms and Babies Act; Inclusion of pregnant and lactating individuals in research (general); Obstetric and gynecologic care in rural and underserved areas (general); impact of closures of ob-gyn units in rural hospitals on patient access to care and maternal morbidity and mortality; Teaching Health Center Graduate Medication Education (general); H.R. 1909, Preventing Maternal Deaths Reauthorization Act of 2025; S. 422/H.R. 999, Right to Contraception Act; S.Res.32 - A resolution designating January 23, 2025, as "Maternal Health Awareness Day"; Telemedicine (general); SHINE for Autumn Act; S. 380/H.R. 1254, Rural Obstetrics Readiness Act; S. 1239/H.R. 2529, Convenient Contraception Act; S. 958, Tech to Save Moms Act; Supporting Healthy Moms and Babies Act; S. 942/H.R. 2028, REDI Act; Reducing Hereditary Cancer Act; H.Res.238, Resolution to Reaffirm Emergency Abortion Care for All; S. 992/H.R. 2040, NEWBORN Act; S. 6/H.R. 21, Born Alive Abortion Survivors Protection Act; Implementation of P.L. 117-328, Pregnant Workers Fairness Act; National Health Service Corps (general); Public Service Loan Forgiveness program (general); H.R. 593, Strengthening Pathways to Health Professions Act; maternal mortality review committees (general); pregnancy as a qualifying life event (general); HIPAA (general); reductions in force at HHS (general); caps on indirect research costs at NIH (general); removal of CDC online guidance (general); Patient-physician relationship (general); Obstetrician-gynecologist workforce (general); Substance use disorder during pregnancy (general); Maternal mental health (general); Coverage for infertility (general); Protections for in vitro fertilization (general); Vaccination (general); Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC) recommendations (general); NIH/NICHD womens health research (general); access to fertility services and treatments.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), White House Office, Executive Office of the President (EOP), Centers For Disease Control & Prevention (CDC), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rebecca |
Lauer |
|
|
|
Erin |
Alston |
|
|
|
Taylor |
Platt |
|
|
|
Rachel |
Tetlow |
|
|
|
Lillie |
Heyman |
|
|
|
Lisa |
Satterfield |
|
|
|
Sarah |
Bogdan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025; H.R. 2586, Reentry Act of 2025; Physician payment under Medicare (general); Graduate medical education (general); Prior authorization in Medicare (general); Medicaid (general); Medicaid free choice of provider requirement; Implementation of P.L. 117-328, Consolidated Appropriations Act, including permanent option for postpartum Medicaid extension; Physician reimbursements under Medicaid (general); Medicaid expansion (general); Medicaid work requirements (general); Medicare conditions of participation.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rebecca |
Lauer |
|
|
|
Erin |
Alston |
|
|
|
Taylor |
Platt |
|
|
|
Rachel |
Tetlow |
|
|
|
Lillie |
Heyman |
|
|
|
Lisa |
Satterfield |
|
|
|
Sarah |
Bogdan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code IMM
16. Specific lobbying issues
S. 916, Stop Shackling and Detaining Pregnant Women Act; S. 709 / H.R. 1585, Conrad State 30 and Physician Access Reauthorization Act; S. 455/H.R. 1061, Protecting Sensitive Locations Act; detention of children in ICE facilities (general)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Homeland Security - Dept of (DHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rebecca |
Lauer |
|
|
|
Lillie |
Heyman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Womens health research (general); Centers for Disease Control and Prevention (CDC); National Institutes of Health (NIH); NIH Office of Research on Womens Health; Health Resources and Services Administration (HRSA); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Alliance for Innovation on Maternal Health (HRSA); Safe Motherhood and Infant Health Program (CDC); Substance Abuse and Mental Health Services Administration (SAMHSA); Agency for Healthcare Research and Quality (AHRQ); National Center for Health Statistics (NCHS); Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC); inclusion of pregnant and lactating people in clinical trials (general); Congressionally Directed Medical Research Program; Title X family planning program; CDC Division of Sexually Transmitted Disease Prevention; Prevention and Public Health Fund; Title VII Health Professions and Title VIII Nursing Workforce Development programs; Medicaid free choice of provider requirement; research into firearm morbidity and mortality prevention at CDC and NIH; rural obstetrics emergency readiness training and grants; neglected surgical conditions (general); H.R.1968, Full-Year Continuing Appropriations and Extensions Act, 2025; FY2026 Labor, Health and Human Services, and Education, and Related Agencies appropriations bill.
17. House(s) of Congress and Federal agencies Check if None
Centers For Disease Control & Prevention (CDC), Natl Institutes of Health (NIH), U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health Resources & Services Administration (HRSA), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rachel |
Tetlow |
|
|
|
Rebecca |
Lauer |
|
|
|
Lillie |
Heyman |
|
|
|
Sarah |
Bogdan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
Abortion policy at the Department of Defense (general); H.R. 1742, Access to Reproductive Care for Servicemembers Act.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rachel |
Tetlow |
|
|
|
Rebecca |
Lauer |
|
|
|
Lillie |
Heyman |
|
|
|
Sarah |
Bogdan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HOM
16. Specific lobbying issues
S. 260/H.R. 820, Bottles and Breastfeeding Equipment Screening Enhancement Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rebecca |
Lauer |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOR
16. Specific lobbying issues
H.R.764/S.280, Global Health, Empowerment and Rights Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rebecca |
Lauer |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
ACE Veterans Act; abortion policy at Department of Veterans Affairs (general)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rebecca |
Lauer |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |